KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) FCF Margin (2016 - 2025)

Historic FCF Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 32.17%.

  • Supernus Pharmaceuticals' FCF Margin fell 625200.0% to 32.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.38%, marking a year-over-year decrease of 160000.0%. This contributed to the annual value of 25.87% for FY2024, which is 76800.0% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its FCF Margin stood at 32.17% for Q3 2025, which was down 625200.0% from 35.1% recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' FCF Margin peaked at 41.98% during Q2 2022, and registered a low of 32.17% during Q3 2025.
  • In the last 5 years, Supernus Pharmaceuticals' FCF Margin had a median value of 25.38% in 2024 and averaged 18.51%.
  • Per our database at Business Quant, Supernus Pharmaceuticals' FCF Margin skyrocketed by 351700bps in 2024 and then plummeted by -625200bps in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' FCF Margin stood at 30.66% in 2021, then crashed by -46bps to 16.57% in 2022, then soared by 65bps to 27.38% in 2023, then decreased by -7bps to 25.38% in 2024, then tumbled by -227bps to 32.17% in 2025.
  • Its FCF Margin stands at 32.17% for Q3 2025, versus 35.1% for Q2 2025 and 20.21% for Q1 2025.